Skip to content

Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study

Liao B, Zhao Y, Wang D, Zhang X, Hao X, Hu M | Journal of the International Society of Sports Nutrition | 2021 | Evidence: moderate

Plain-language summary

Published 2021 in Journal of the International Society of Sports Nutrition, this work by Liao B and collaborators tackles a specific question within benefits-focused NMN/NAD+ research.

Key findings reported by the authors

  • 6-week NMN dose-response (300, 600, 1200 mg/day) in amateur runners
  • VO2 and ventilatory thresholds improved dose-dependently
  • Time-to-exhaustion improved at higher doses

What this means for Malaysian buyers

For readers in Malaysia weighing whether to start or continue NMN supplementation, this paper sits at the moderate end of the evidence spectrum. Moderate-tier evidence usually means a small human trial or a well-designed mouse study; helpful for hypothesis-building but not for hard recommendations. Findings here are most directly relevant to benefits decisions, with secondary relevance to dosage. Our editorial methodology weights human placebo-controlled trials above mouse mechanistic work above review articles.

Where we cite this paper

← Back to research index